EP Patent

EP3759127A4 — COMPOUNDS AND METHODS FOR MODULATION OF AMYLOID BETA PRECURSOR PROTEIN

Assigned to Rosalind Franklin University of Medicine and Science · Expires 2022-03-30 · 4y expired

What this patent protects

Patent listed against eplontersen-sodium.

Drugs covered by this patent

eplontersen-sodium (EPLONTERSEN SODIUM)

Patent Metadata

Patent number: EP3759127A4
Jurisdiction: EP
Classification: —
Expires: 2022-03-30
Drug substance claim: No
Drug product claim: No
Assignee: Rosalind Franklin University of Medicine and Science
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.